Document ID: FDA-2015-N-0126-0003
Agency: fda
Document Type: Notice
Title: Revocation of Authorization of Emergency Use of an In Vitro Diagnostic Device for Detection of Ebola Virus
Posted Date: 2018-08-02T04:00Z

[Federal Register Volume 83, Number 149 (Thursday, August 2, 2018)]
[Notices]
[Pages 37813-37816]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16537]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-0126]

Revocation of Authorization of Emergency Use of an In Vitro 
Diagnostic Device for Detection of Ebola Virus

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
revocation of the Emergency Use Authorization (EUA) (the Authorization) 
issued to Zalgen Labs, LLC for the ReEBOV Antigen Rapid Test. FDA 
revoked this Authorization on May 18, 2018, under the Federal Food, 
Drug, and Cosmetic Act (FD&C Act), as requested by Zalgen Labs, LLC by 
letter dated March 1, 2018. The revocation, which includes an 
explanation of the reasons for revocation, is reprinted in this 
document.

DATES: The Authorization is revoked as of May 18, 2018.

ADDRESSES: Submit written requests for single copies of the revocation 
to the Office of Counterterrorism and Emerging Threats, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4338, Silver 
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist 
that office in processing your request or include a Fax number to which 
the revocation may be sent. See the SUPPLEMENTARY INFORMATION section 
for electronic access to the revocation.

FOR FURTHER INFORMATION CONTACT: Michael Mair, Office of 
Counterterrorism and Emerging Threats, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 1, Rm. 4336, Silver Spring, MD 20993-
0002, 301-796-8510 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION:

I. Background

    Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) as amended by the 
Project BioShield Act of 2004 (Pub. L. 108-276) and the Pandemic and 
All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5) 
allows FDA to strengthen the public health protections against 
biological, chemical, nuclear, and radiological agents. Among other 
things, section 564 of the FD&C Act allows FDA to authorize the use of 
an unapproved medical product or an unapproved use of an approved 
medical product in certain situations. On February 24, 2015, FDA issued 
an EUA to Corgenix, Inc. for the ReEBOV Antigen Rapid Test, subject to 
the terms of the Authorization. Notice of the issuance of the 
Authorization was published in the Federal Register on June 5, 2015 (80 
FR 32140), as required by section 564(h)(1) of the FD&C Act. In 
response to requests from Zalgen Labs, LLC and Corgenix, Inc. to 
transfer ownership of the EUA for the ReEBOV Antigen Rapid Test from 
Corgenix, Inc. to Zalgen Labs, LLC, FDA amended and reissued the EUA to 
Zalgen Labs, LLC

[[Page 37814]]

in its entirety on November 3, 2016. Under section 564(g)(2), the 
Secretary of Health and Human Services may revoke an EUA if, among 
other things, the criteria for issuance are no longer met or other 
circumstances make such revocation appropriate to protect the public 
health or safety.

II. EUA Revocation Request for an In Vitro Diagnostic Device for 
Detection of the Ebola Virus

    Pursuant to a request from Zalgen Labs, LLC on March 1, 2018, FDA 
revoked the EUA for the ReEBOV Antigen Rapid Test on May 18, 2018, 
because the criteria for issuance were no longer met and these 
circumstances made such revocation appropriate to protect the public 
health or safety.

III. Electronic Access

    An electronic version of this document and the full text of the 
revocation are available on the internet at https://www.regulations.gov.

IV. The Revocation

    Having concluded that the criteria for revocation of the 
Authorization under section 564(g) of the FD&C Act are met, FDA has 
revoked the EUA for Zalgen Labs, LLC's ReEBOV Antigen Rapid Test. The 
revocation in its entirety follows and provides an explanation of the 
reasons for revocation, as required by section 564(h)(1) of the FD&C 
Act.

BILLING CODE 4164-01-P

[[Page 37815]]

[GRAPHIC] [TIFF OMITTED] TN02AU18.006

[[Page 37816]]

[GRAPHIC] [TIFF OMITTED] TN02AU18.007

    Dated: July 27, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-16537 Filed 8-1-18; 8:45 am]
 BILLING CODE 4164-01-C